← Eichor
Study identifier: NCT05539196 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Condition: Movement Disorders · Neurology · Parkinsons Disease  ·  Sponsor: InSightec

PhaseN/A
Planned participants60
Who can joinAll sexes, 30 Years to 99 Years
Healthy volunteersNo

About this study

This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.

This description comes directly from the study's public registry record.

Talk to the study team

Kingsley Nwaogu  ·  2143048265  ·  clinicalresearchquestions@insightec.com

Julia Zhu  ·  2148462577  ·  clinicalresearchquestions@insightec.com

Always discuss trial participation with your own doctor first.

Locations (5)

University of Maryland, BaltimoreBaltimore, Maryland, United StatesRecruiting
Weill Cornell MedicineNew York, New York, United StatesRecruiting
University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting
University of Texas Southwestern Medical CenterDallas, Texas, United StatesRecruiting
Ohnishi Neurological CenterAkashi, Hyōgo, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05539196